Navigation Links
New Acetadote® Formulation Now Available in the U.S.
Date:3/22/2011

NASHVILLE, Tenn., March 22, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that it has completed the U.S. launch of its new formulation of Acetadote® (acetylcysteine) Injection, the Company's product used to treat acetaminophen poisoning. The proprietary new formulation, which does not contain ethylene diamine tetracetic acid (EDTA) or any other stabilization or chelating agents, is now stocked at wholesalers serving hospitals across the country.

Acetadote is used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter pain relief and fever-reducing products. The new formulation was approved by the U.S. Food and Drug Administration (FDA) in January and replaces the previously marketed product. Acetaminophen continues to be the leading cause of poisonings reported by hospital emergency rooms in the United States(1), and Acetadote has become a standard of care for treating this potentially life-threatening condition.

"We are pleased to make this next generation of Acetadote available to the hospital community and the growing number of patients who will benefit from it," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "This launch marks an important milestone in our strategy to support our products by improving upon existing formulations and expanding into new patient populations."

Cumberland has worked with U.S. wholesalers to transition inventories from the original to the new formulation. Shipments of the original formulation have ceased and the Company is now filling all Acetadote orders with the new product. A communications campaign has been initiated to support poison control centers and U.S. hospital pharmacists as they transition to the new formulation, which includes an extended shelf life of 30 months, up from 24 months for the o
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
3. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
4. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
7. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
8. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
9. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
10. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
11. New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
... Announces Positive Top Line Results of its Clinical Study ... Mass., May 11 Logical Therapeutics, Inc (Logical), a ... treat diseases associated with inflammation, today announced that Peter ... has been elected to the Company,s Board of Directors. ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 3Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 4
(Date:7/30/2015)... ... 2015 , ... The New Jersey Innovation Institute (NJII), acting ... Health, has received a $2.9 million grant from the Office of the National ... and Human Services (HHS). NJII will help the Department of Health ensure the ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
(Date:7/30/2015)... ORLEANS (PRWEB) , ... July 30, 2015 , ... Author ... and take charge of their health in his new self-help book, “ Consciously Healing ... Llanos’ new book promotes a simple message: “If we take responsibility for ourselves, we ...
(Date:7/30/2015)... ... , ... Summer is the dry eye season, especially in parts of the ... and hot 2015 summer season and the dry eye rate in the hot spots ... the 2015 summer season and identify the primary dry eye hot spots on her ...
(Date:7/30/2015)... ... July 30, 2015 , ... HEALTHCAREfirst , the leading ... announced today that it is hosting a free webinar detailing the 2016 proposed rule ... HEALTHCAREfirst Consultant and former Vice President of Regulatory Affairs for the National Association for ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2
... , NEW YORK, Dec. 10 SIRIUS ... Doctor Radio Reports: Kids and Video Games - What ... by journalist Perri Peltz on which she and a panel of experts ... effects they have on children. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO ) , ...
... , SALEM, Ore., Dec. 10 West Coast Bank,s ... Bears for children hospitalized at the Salem Hospital Pediatric Wing and ... Bears at the branch, 5686 Commercial St. SE, Suite 110 on ... BSN CPN, Nurse Manager of Pediatrics at Salem Hospital said, "The ...
... of alcoholic beverages (at least three to four drinks per ... a 30 percent increased risk of breast cancer recurrence, according ... may be most susceptible to the effects of alcohol on ... of this study will be presented December 9-13 at the ...
... to die or be disabled by midlife, study finds, , THURSDAY, ... a man,s risk of dying or becoming disabled by the time ... findings are from a study that began following 411 South London ... those who at age 10 displayed antisocial behavior (such as skipping ...
... ... leader in Sales and Operations Planning (S&OP) solutions, announced a program ... JDA The Steelwedge "i2 Exchange Program" address i2 customers that ... recently announced merger between i2 and JDA (formerly Manugistics), or are ...
... , RANCHO CORDOVA, Calif., Dec. 10 ThermoGenesis Corp. (Nasdaq: ... processing and storing adult stem cells, said today that Craig ... industry experience, has been named to the Company,s board of ... to six. , Moore is currently associated with several public ...
Cached Medicine News:Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 4Health News:Alcohol consumption may increase breast cancer recurrence risk 2Health News:Bad Behavior as a Kid Linked to Early Death in Men 2Health News:Leading Sales and Operations Planning (S&OP) Provider Steelwedge Announces i2 Exchange Program 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 3Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 4
Inquire...
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
... and Hypergamma Controls are designed ... agarose gels or Sebia's ... unique control manufacturing process preserves ... other serum components, presenting a ...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Medicine Products: